Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia

Jose Cadena, George Richard Thompson, Tony T. Ho, Edward Medina, Darrel W. Hughes, Thomas F. Patterson

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Tumor necrosis factor α antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume64
Issue number3
DOIs
StatePublished - Jul 2009
Externally publishedYes

Keywords

  • Adalimumab
  • Cryptococcus
  • Immune reconstitution
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor α blocker adalimumab in cryptococcal pneumonia'. Together they form a unique fingerprint.

  • Cite this